Before taking this medicine

ORENCIA should be used with caution in patients with underlying infections, compromised immune systems, or respiratory conditions like COPD, and requires proper screening before initiation.

Warnings and Precautions for ORENCIA Use

ORENCIA may increase the risk of infections, especially when used concurrently with TNF inhibitors, other biologics, or JAK inhibitors. Patients should be screened for latent tuberculosis (TB) and viral hepatitis before starting therapy. The drug can also suppress the effectiveness of live vaccines, so vaccination should be updated before initiation, with live vaccines avoided within three months of discontinuation. Patients with chronic obstructive pulmonary disease (COPD) may experience more frequent respiratory adverse events. Serious infections, hypersensitivity reactions, and reactivation of viruses like CMV and EBV, particularly in aGVHD patients, are also significant concerns.